Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05068726 · ClinicalTrials.gov registry record
Clinical Utility of FES F18 PET/CT in Metastatic Breast Cancer Patients
A clinical trial, sponsored by GE Healthcare.
- Terminated
- Registry status
- 51
- Enrollment target
NCT05068726 is a clinical trial that was terminated before completion, run by GE Healthcare. The registered enrollment target is 51 participants.
The verdict
NCT05068726 was terminated before completion, sponsored by GE Healthcare.
- TERMINATED
- Registry status
- 51 participants
- Enrollment target
Study Summary
This is a phase 4, multi-center, open-label, prospective cohort study to evaluate the clinical utility of Fluoroestradiol F18 (Cerianna) PET/CT to guide therapeutic management in ER-positive, HER2-negative metastatic breast cancer patients with progressive disease on first-line standard-of-care hormonal therapy. All patients will undergo a Cerianna PET/CT scan. The treating physician will complete a standardized questionnaire to indicate the second-line therapeutic management plan before the scheduled Cerianna PET/CT. After interpretation of Cerianna PET/CT by local radiologist or nuclear medicine physician, the treating physician will fill out a similar questionnaire to specify the final therapeutic decision. The proportion of patients with a change in therapeutic management plan based on Cerianna PET/CT results will be the primary endpoint. During the study follow-up period of 18 months, data on standard-of-care imaging, treatments/procedures received, and clinical outcomes will be collected. Patients will be asked to complete a health-related quality of life questionnaire at their screening, 6-month, and 18-month visit. Secondary endpoints include visual and quantitative heterogeneity assessment of tumor Cerianna uptake, and PFS rates at 6 months and 18 months after Cerianna PET/CT, which will be assessed between patients with and without a change in therapeutic management plan. Maximum duration of follow-up for each patient: 20 months. First patient first visit to last patient last visit: estimated 36 months.
Interventions
- DRUG 18F Fluoroestradiol Radiopharmaceutical with PET/CT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2023-01-05 |
| Est. Completion | 2024-06-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05068726
The ClinicalTrials.gov registry entry for NCT05068726 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GE Healthcare, which has 99 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 18F Fluoroestradiol Radiopharmaceutical with PET/CT is the first listed.
NCT05068726 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05068726 about?
NCT05068726 is a clinical study titled "Clinical Utility of FES F18 PET/CT in Metastatic Breast Cancer Patients". This is a phase 4, multi-center, open-label, prospective cohort study to evaluate the clinical utility of Fluoroestradiol F18 (Cerianna) PET/CT to guide therapeutic management in ER-positive, HER2-negative metastatic breast cancer patients with progressive disease on first-line standard-of-care horm...
What is the current status of trial NCT05068726?
This trial is currently terminated. The enrollment target is 51 participants. The study started on 2023-01-05. Estimated completion is 2024-06-01.
What interventions are being tested in trial NCT05068726?
The interventions under investigation include: 18F Fluoroestradiol Radiopharmaceutical with PET/CT (DRUG).
Who is sponsoring clinical trial NCT05068726?
This trial is sponsored by GE Healthcare, which has 99 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.